Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-04-20Clinical Trial Update: A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant [Phase 3]
Phase 3 trial comparing daratumumab plus lenalidomide versus lenalidomide alone as maintenance in newly diagnosed multiple myeloma patients …
-
CLINICAL_TRIALS trial_result · 2025-04-20Clinical Trial Update: A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant [Phase 3]
Phase 3 trial comparing daratumumab plus lenalidomide versus lenalidomide alone as maintenance in newly diagnosed, MRD-positive multiple mye…
-
CLINICAL_TRIALS research · 2025-04-20Clinical Trial Update: PRO and Wearable Data Insights From Individuals With R/R Multiple Myeloma [NA]
This update describes a clinical study exploring patient-reported outcomes and wearable data in people with relapsed/refractory multiple mye…
-
CLINICAL_TRIALS trial_result · 2025-04-17Clinical Trial Update: Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma [Phase 1]
A Phase 1 study of CC-93269, a BCMA x CD3 T cell engaging antibody, in relapsed and refractory multiple myeloma has been terminated.
-
CLINICAL_TRIALS trial_result · 2025-04-16Clinical Trial Update: Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H) [Phase 2]
Phase 2 MATCH subprotocol study evaluating copanlisib as a targeted treatment for cancers with PTEN expression. The trial is currently activ…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-04-16Clinical Trial Update: Phase 1 Study of OPB-31121 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma [Phase 1]
A Phase 1 study evaluating OPB-31121 in relapsed or refractory Non-Hodgkin's Lymphoma and Multiple Myeloma has completed.
-
CLINICAL_TRIALS research · 2025-04-16Clinical Trial Update: Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma [Phase 2]
This Phase 2 clinical trial is evaluating daratumumab- and carfilzomib-based induction, consolidation, and maintenance therapy in transplant…
-
CLINICAL_TRIALS safety_alert · 2025-04-15Clinical Trial Update: Post Marketing Surveillance on Safety Evaluation of POMALYST® (Pomalidomide) Treatment of Multiple Myeloma in Korea
Post-marketing safety surveillance study of pomalidomide (POMALYST) for multiple myeloma conducted in Korea has completed.
-
CLINICAL_TRIALS research · 2025-04-15Clinical Trial Update: LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study
Ongoing University of Alberta-sponsored LONGEVITI study, LIVInG With chrONic Cancer TrEatments, is currently recruiting to evaluate cancer t…
-
CLINICAL_TRIALS trial_result · 2025-04-13Clinical Trial Update: A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma [Phase 3]
A Phase 3 study evaluating daratumumab in transplant-eligible patients with previously untreated multiple myeloma has completed. Results wer…
-
CLINICAL_TRIALS research · 2025-04-13Clinical Trial Update: A Clinical Trial Evaluating the Safety Tolerability, Radiation Absorption Dose, Distribution, PET Imaging and Histological Expression of 68Ga-NOTA-SCH001 in Patients With Multiple Myeloma [NA]
This document outlines a clinical trial evaluating the safety, tolerability, radiation dose, distribution, PET imaging, and histological exp…
-
CLINICAL_TRIALS research · 2025-04-11Clinical Trial Update: Aponermin, Pomalidomide, Dexamethasone for Patients With Relapsed/ Refractory Multiple Myeloma [NA]
This clinical trial update describes a study evaluating a combination of Aponermin, pomalidomide, and dexamethasone in relapsed or refractor…
-
CLINICAL_TRIALS trial_result · 2025-04-10Clinical Trial Update: An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments [Phase 1]
Phase 1 open-label, dose-escalation study in Japanese patients with relapsed/refractory multiple myeloma who have failed prior anti-myeloma …
-
CLINICAL_TRIALS research · 2025-04-10Clinical Trial Update: Analysis of the Resistance and Sensitivity Mechanisms to Teclistamab by Focusing on Single Immune Cell Examination [NA]
Clinical trial analyzing resistance and sensitivity mechanisms to teclistamab by single immune cell examination in multiple myeloma; current…
-
CLINICAL_TRIALS research · 2025-04-10Clinical Trial Update: Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM [Phase 2]
A Phase 2 clinical trial update evaluating Isatuximab plus lenalidomide-dexamethasone (Rd) versus Rd in elderly patients (age 70 and older) …
-
CLINICAL_TRIALS research · 2025-04-09Clinical Trial Update: Biomarkers in Multiple Myeloma [NA]
Recruitment is ongoing for a biomarker-focused clinical trial in newly diagnosed multiple myeloma patients, sponsored by Centre Hospitalier …
-
CLINICAL_TRIALS research · 2025-04-09Clinical Trial Update: Multi-center Screening for Serum M Protein
A multi-center screening trial is planned to screen for serum M protein in subjects with Monoclonal gammopathy and Multiple myeloma; recruit…
-
CLINICAL_TRIALS trial_result · 2025-04-08Clinical Trial Update: Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U) [Phase 2]
Phase 2 MATCH subprotocol U update on defactinib (VS-6063) for cancers with NF2 genetic changes, with results posted and the trial listed as…
-
CLINICAL_TRIALS research · 2025-04-08Clinical Trial Update: VitD3 Supplementation in Patients With Multiple Myeloma [EARLY_Phase 1]
A Phase 1 early trial evaluating Vitamin D3 (cholecalciferol) supplementation in patients with multiple myeloma is currently recruiting.
-
CLINICAL_TRIALS research · 2025-04-06Clinical Trial Update: Efficacy of Sequential BCMA CAR-T Cell Therapy Following Autologous Hematopoietic Stem Cell Transplantation in Transplant-eligible Newly Diagnosed Multiple Myeloma [Phase 1]
Phase 1 clinical trial evaluating sequential BCMA-targeted CAR-T cell therapy after autologous stem cell transplantation in transplant-eligi…
-
CLINICAL_TRIALS research · 2025-04-06Clinical Trial Update: CAR-T Cell Therapy Combined With Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Multiple Myeloma [Phase 1]
A Phase 1 clinical trial is evaluating a combination of CAR-T cell therapy with an allogeneic hematopoietic stem cell transplant for relapse…
-
CLINICAL_TRIALS research · 2025-04-06Clinical Trial Update: Screening and Therapeutic Monitoring of Multiple Myeloma by MALDI-TOF MS Analysis
This clinical trial update describes evaluating MALDI-TOF mass spectrometry for screening and monitoring treatment response in multiple myel…
-
CLINICAL_TRIALS research · 2025-04-06Clinical Trial Update: A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse." [Phase 2]
Phase 2 open-label multicenter trial evaluating ixazomib, iberdomide, and dexamethasone in elderly patients with multiple myeloma at first r…
-
CLINICAL_TRIALS research · 2025-04-04Clinical Trial Update: The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors [Phase 1, Phase 2]
Ongoing Phase 1/Phase 2 trials are evaluating CAR-T cell therapy for relapsed or refractory malignant hematologic tumors, including aggressi…
-
CLINICAL_TRIALS trial_result · 2025-04-03Clinical Trial Update: CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma [Phase 1]
Phase 1 study of CID-103, an anti-CD38 antibody, in previously treated relapsed or refractory multiple myeloma has completed. The trial was …